Literature DB >> 10608802

The new kallikrein-like gene, KLK-L2. Molecular characterization, mapping, tissue expression, and hormonal regulation.

G M Yousef1, E P Diamandis.   

Abstract

Since in rodents the kallikreins are represented by a large multi-gene family, the restriction of this family in humans to three genes is somewhat surprising. In an effort to identify new human kallikrein genes, we examined a genomic area of about 300 kilobases on chromosome 19q13.3-q13.4, a region that contains most of the currently known kallikreins. By using the positional candidate approach, we were able to identify a new gene named KLK-L2 (for kallikrein- like gene 2). Screening of human EST libraries allowed us to delineate the full genomic and cDNA structure of the new gene. KLK-L2 consists of 5 coding exons and 4 introns and has significant similarities to other members of the kallikrein multi-gene family. Homology studies suggest that the protein is likely secreted. KLK-L2 is expressed mainly in breast, brain, and testis and to a lesser extent in many other tissues. KLK-L2 is up-regulated by estrogens and progestins in the breast cancer cell line BT-474.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10608802     DOI: 10.1074/jbc.274.53.37511

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

1.  Detection of tissue kallikrein and kinin B1 and B2 receptor mRNAs in human brain by in situ RT-PCR.

Authors:  R Mahabeer; S Naidoo; D M Raidoo
Journal:  Metab Brain Dis       Date:  2000-12       Impact factor: 3.584

2.  Three dysregulated miRNAs control kallikrein 10 expression and cell proliferation in ovarian cancer.

Authors:  N M A White; T-F F Chow; S Mejia-Guerrero; M Diamandis; Y Rofael; H Faragalla; M Mankaruous; M Gabril; A Girgis; G M Yousef
Journal:  Br J Cancer       Date:  2010-03-30       Impact factor: 7.640

3.  Identification and functional analysis of human transcriptional promoters.

Authors:  Nathan D Trinklein; Shelley J Force Aldred; Alok J Saldanha; Richard M Myers
Journal:  Genome Res       Date:  2003-02       Impact factor: 9.043

4.  Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer.

Authors:  Haiyan Si; Xiaoming Sun; Yingjian Chen; Yuan Cao; Shimin Chen; Huanchun Wang; Chengjin Hu
Journal:  J Cancer Res Clin Oncol       Date:  2012-09-30       Impact factor: 4.553

5.  Down-regulation of kallikrein-related peptidase 5 (KLK5) expression in breast cancer patients: a biomarker for the differential diagnosis of breast lesions.

Authors:  Margaritis Avgeris; Georgia Papachristopoulou; Athanasios Polychronis; Andreas Scorilas
Journal:  Clin Proteomics       Date:  2011-05-31       Impact factor: 3.988

6.  Transcriptional upregulation of human tissue kallikrein 6 in ovarian cancer: clinical and mechanistic aspects.

Authors:  S J C Shan; A Scorilas; D Katsaros; E P Diamandis
Journal:  Br J Cancer       Date:  2007-01-29       Impact factor: 7.640

7.  Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer.

Authors:  H Kim; A Scorilas; D Katsaros; G M Yousef; M Massobrio; S Fracchioli; R Piccinno; G Gordini; E P Diamandis
Journal:  Br J Cancer       Date:  2001-03-02       Impact factor: 7.640

8.  Kallikrein gene downregulation in breast cancer.

Authors:  G M Yousef; G M Yacoub; M-E Polymeris; C Popalis; A Soosaipillai; E P Diamandis
Journal:  Br J Cancer       Date:  2004-01-12       Impact factor: 7.640

9.  Prognostic value of kallikrein-related peptidase 7 (KLK7) mRNA expression in advanced high-grade serous ovarian cancer.

Authors:  Weiwei Gong; Yueyang Liu; Eleftherios P Diamandis; Marion Kiechle; Holger Bronger; Julia Dorn; Tobias Dreyer; Viktor Magdolen
Journal:  J Ovarian Res       Date:  2020-10-21       Impact factor: 4.234

10.  Kallikrein gene family as biomarkers for recurrent prostate cancer.

Authors:  Fatma Busra Boyukozer; Esra Guzel Tanoglu; Mustafa Ozen; Michael Ittmann; Elif Sibel Aslan
Journal:  Croat Med J       Date:  2020-10-31       Impact factor: 1.351

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.